Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News Analysis
  • Published:

Will Biogen and Teva challenge Berlex in MS?

Bio/Technology volume 12, pages 1317–1318 (1994)Cite this article

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Authors
  1. Joseph Alper
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Alper, J. Will Biogen and Teva challenge Berlex in MS?. Nat Biotechnol 12, 1317–1318 (1994). https://doi.org/10.1038/nbt1294-1317

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt1294-1317

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing